| CAS NO: | 453590-24-4 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 1mg | 电议 |
| 5mg | 电议 |
| Cas No. | 453590-24-4 |
| Canonical SMILES | NC1=C2C(OC(C3=CC=C(OC)C=C3)=C2)=NC=N1 |
| 分子式 | C13H11N3O2 |
| 分子量 | 241.25 |
| 溶解度 | DMSO: 5 mg/mL (20.73 mM; ultrasonic and warming and heat to 80℃) |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | TIE-2/VEGFR-2 kinase-IN-1 is used for the synthesis of TIE-2 and/or VEGFR-2 inhibitors, extracted from patent WO2003022852, example 14. TIE-2/VEGFR-2 kinase-IN-1 is used for the study of diseases associated with inappropriate angiogenesis[1]. Angiopoieten 1 is a ligand for the endotheiium-specific receptor tyrosine kinase, TIE-2 is a novel angiogenic factor[1].Inhibition of TIE-2 is expected to serve to disrupt remodeling and maturation of new vasculature initiated by angiogenesis thereby disrupting the angiogenic process. Inhibition at the kinase domain binding site of VEGFR-2 would block phosphorylation of tyrosine residues and serve to disrupt initiation of angiogenesis. [1]. Jerry Leroy Adams, et al. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors. Patent WO2003022852. |
m.cnreagent.com